Alberto Chiarugi Selected Research

Poly (ADP-Ribose) Polymerase-1

2/2012	Targeting poly(ADP-ribose) polymerase-1 as a promising approach for immunomodulation in multiple sclerosis?
7/2011	PARP-1 inhibition prevents CNS migration of dendritic cells during EAE, suppressing the encephalitogenic response and relapse severity.
7/2005	Poly(ADP-ribosyl)ation and stroke.
4/2005	Nuclear poly(ADP-ribose) polymerase-1 rapidly triggers mitochondrial dysfunction.
6/2003	Novel isoquinolinone-derived inhibitors of poly(ADP-ribose) polymerase-1: pharmacological characterization and neuroprotective effects in an in vitro model of cerebral ischemia.
4/2003	Poly(ADP-ribose) polymerase-1 activity promotes NF-kappaB-driven transcription and microglial activation: implication for neurodegenerative disorders.
11/2002	Inhibitors of poly(ADP-ribose) polymerase-1 suppress transcriptional activation in lymphocytes and ameliorate autoimmune encephalomyelitis in rats.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Alberto Chiarugi Research Topics

Disease

9	Migraine Disorders (Migraine) 11/2022 - 04/2002
9	Brain Injuries (Brain Injury) 06/2021 - 11/2002
8	Brain Ischemia (Cerebral Ischemia) 11/2018 - 06/2003
7	Pain (Aches) 11/2022 - 07/2015
7	Stroke (Strokes) 01/2018 - 12/2006
7	Neoplasms (Cancer) 01/2018 - 02/2005
7	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 02/2013 - 11/2002
6	Inflammation (Inflammations) 01/2018 - 04/2002
5	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 06/2021 - 11/2002
5	Mitochondrial Diseases (Mitochondrial Disease) 01/2017 - 04/2005
4	Multiple Sclerosis 01/2021 - 05/2011
4	Infarction (Infarctions) 11/2018 - 01/2006
4	Brain Infarction 01/2018 - 04/2003
4	Necrosis 01/2007 - 11/2002
3	Headache (Headaches) 01/2022 - 03/2021
3	Disease Progression 01/2020 - 01/2018
3	Fever (Fevers) 08/2017 - 02/2013
3	Ischemic Stroke 11/2016 - 07/2005
3	Hypothermia 02/2013 - 06/2012
2	Secondary Headache Disorders 11/2022 - 03/2021
2	Prescription Drug Overuse 01/2022 - 01/2022
2	Cluster Headache (Cluster Headaches) 01/2022 - 01/2020
2	Demyelinating Diseases (Demyelinating Disease) 06/2021 - 07/2011
2	Neuralgia (Stump Neuralgia) 01/2020 - 07/2015
2	Hyperalgesia 10/2018 - 07/2015
2	Prostatic Neoplasms (Prostate Cancer) 01/2018 - 10/2008
2	Neuroblastoma 01/2018 - 06/2014
2	Neuroinflammatory Diseases 02/2012 - 04/2003
2	Ischemia 02/2009 - 11/2002
1	Chronic Pain 11/2022
1	Hypersensitivity (Allergy) 11/2022
1	Pneumonia (Pneumonitis) 11/2021
1	COVID-19 11/2021
1	Schizophrenia (Dementia Praecox) 06/2020
1	Allergic Conjunctivitis (Giant Papillary Conjunctivitis) 01/2019
1	Wounds and Injuries (Trauma) 11/2018
1	Cerebrovascular Disorders (Cerebrovascular Occlusion) 11/2018
1	Brain Hypoxia-Ischemia (Hypoxia Ischemia, Brain) 11/2018

Drug/Important Bio-Agent (IBA)

10	Proteins (Proteins, Gene)FDA Link 11/2022 - 11/2002
10	EnzymesIBA 10/2018 - 06/2003
9	Pharmaceutical PreparationsIBA 01/2020 - 04/2002
7	Adenosine Triphosphate (ATP)IBA 06/2021 - 11/2002
7	NAD (NADH)IBA 01/2018 - 11/2002
7	Poly (ADP-Ribose) Polymerase-1IBA 02/2012 - 11/2002
5	DexpramipexoleIBA 06/2021 - 01/2018
5	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 11/2016 - 01/2009
4	Histone Deacetylase InhibitorsIBA 11/2022 - 05/2011
4	CytokinesIBA 01/2018 - 11/2002
4	NF-kappa B (NF-kB)IBA 01/2012 - 04/2002
3	Calcitonin Gene-Related PeptideIBA 11/2022 - 01/2022
3	eletriptan (Relpax)FDA Link 11/2022 - 01/2017
3	Analgesics (Analgesic Drugs)IBA 01/2022 - 12/2015
3	HMGB1 Protein (HMG1)IBA 01/2019 - 06/2011
3	Indoleamine-Pyrrole 2,3,-Dioxygenase (Indoleamine 2,3 Dioxygenase)IBA 01/2018 - 02/2006
3	Adenosine Monophosphate (AMP)IBA 12/2013 - 02/2013
2	Monoclonal AntibodiesIBA 11/2022 - 01/2022
2	AntibodiesIBA 11/2022 - 01/2022
2	Tryptamines (Triptans)IBA 11/2022 - 01/2017
2	fremanezumabIBA 01/2022 - 11/2021
2	galcanezumabIBA 01/2022 - 01/2022
2	erenumabIBA 01/2022 - 01/2022
2	ProstaglandinsIBA 10/2018 - 02/2013
2	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 08/2017 - 12/2015
2	Ibuprofen (Motrin)FDA LinkGeneric 08/2017 - 12/2015
2	Transcription Factors (Transcription Factor)IBA 11/2016 - 02/2009
2	Succinate Dehydrogenase (Fumarate Reductase)IBA 06/2014 - 05/2009
2	Adenosine (Adenocard)FDA LinkGeneric 12/2013 - 02/2013
2	Adenosine A1 ReceptorIBA 02/2013 - 02/2013
2	NucleotidesIBA 02/2013 - 11/2012
2	Oxygen (Dioxygen)IBA 01/2012 - 01/2006
2	Glucose (Dextrose)FDA LinkGeneric 01/2012 - 01/2006
2	Messenger RNA (mRNA)IBA 01/2012 - 02/2009
2	Neuroprotective AgentsIBA 01/2006 - 06/2003
2	Poly Adenosine Diphosphate RiboseIBA 07/2005 - 04/2003
2	Poly(ADP-ribose) Polymerase InhibitorsIBA 06/2003 - 04/2003
2	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 11/2002 - 11/2002
1	PanobinostatIBA 11/2022
1	Capsaicin (Zostrix)FDA Link 11/2022
1	givinostatIBA 11/2022
1	Prednisone (Sone)FDA LinkGeneric 01/2022
1	LithiumIBA 01/2022
1	Verapamil (Calan)FDA LinkGeneric 01/2022
1	CuprizoneIBA 06/2021
1	Methadone (Dolophine)FDA LinkGeneric 03/2021
1	Myelin-Oligodendrocyte GlycoproteinIBA 01/2021
1	Antipsychotic Agents (Antipsychotics)IBA 06/2020
1	Aripiprazole (Abilify)FDA Link 06/2020
1	Sodium Channels (Sodium Channel)IBA 01/2020
1	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2020
1	benzothiazoleIBA 01/2020
1	Sumatriptan (Imigran)FDA LinkGeneric 01/2020
1	SodiumIBA 01/2020
1	Dexamethasone (Maxidex)FDA LinkGeneric 12/2019
1	Indomethacin (Indometacin)FDA LinkGeneric 10/2018
1	NeuropeptidesIBA 10/2018
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 10/2018

Therapy/Procedure

6	Therapeutics 01/2020 - 04/2002
2	Induced Hypothermia 02/2013 - 02/2013
1	Retreatment 01/2022
1	Analgesia 01/2020